0001183740-22-000039.txt : 20220216 0001183740-22-000039.hdr.sgml : 20220216 20220216163120 ACCESSION NUMBER: 0001183740-22-000039 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20220216 DATE AS OF CHANGE: 20220216 EFFECTIVENESS DATE: 20220216 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LexaGene Holdings Inc. CENTRAL INDEX KEY: 0001450416 IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0228 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-377062 FILM NUMBER: 22643993 BUSINESS ADDRESS: STREET 1: 500 CUMMINGS CTR., SUITE 4550 CITY: BEVERLY STATE: MA ZIP: 01915 BUSINESS PHONE: 800-215-1824 MAIL ADDRESS: STREET 1: 500 CUMMINGS CTR., SUITE 4550 CITY: BEVERLY STATE: MA ZIP: 01915 FORMER COMPANY: FORMER CONFORMED NAME: STONESHIELD CAPITAL CORP. DATE OF NAME CHANGE: 20100729 FORMER COMPANY: FORMER CONFORMED NAME: STONESHIELD CAPITAL CORP DATE OF NAME CHANGE: 20081119 D/A 1 primary_doc.xml X0708 D/A LIVE 0001450416 LexaGene Holdings Inc. 500 CUMMINGS CTR., SUITE 4550 BEVERLY MA MASSACHUSETTS 01915 800-215-1824 BRITISH COLUMBIA, CANADA Wolfeye Resource Corp. STONESHIELD CAPITAL CORP. STONESHIELD CAPITAL CORP Corporation true JOHN (JACK) REGAN 500 Cummings Ctr., Suite 4550 Beverly MA MASSACHUSETTS 01915 Executive Officer Director CEO JEFFREY MITCHELL 500 Cummings Ctr., Suite 4550 Beverly MA MASSACHUSETTS 01915 Executive Officer CFO STEVEN ARMSTRONG 500 Cummings Ctr., Suite 4550 Beverly MA MASSACHUSETTS 01915 Executive Officer COO STEPHEN J MASTROCOLA 500 Cummings Ctr., Suite 4550 Beverly MA MASSACHUSETTS 01915 Director THOMAS R SLEZAK 500 Cummings Ctr., Suite 4550 Beverly MA MASSACHUSETTS 01915 Director JANE SYKES 500 Cummings Ctr., Suite 4550 Beverly MA MASSACHUSETTS 01915 Director JOSEPH CARUSO 500 Cummings Ctr., Suite 4550 Beverly MA MASSACHUSETTS 01915 Director Biotechnology Decline to Disclose 06b true 0001183740-20-000212 2022-02-07 true true true true true Units, each comprised of a share and one warrant. Each warrant is exercisable into a share at $0.35 (C$0.45) per share until February 7, 2025. false 0 8131750 3541246 4590504 Total Offering Amount equals the price of Units (13,115,725 x $0.27 | C$0.35), plus the aggregate exercise price of the underlying warrants (13,115,725 x $0.35 | C$0.45). There is no assurance that the warrants, expiring Feb. 7, 2025, will be exercised. false 1 0 0 0 false LexaGene Holdings Inc. /s/ Jeffrey Mitchell Jeffrey Mitchell CFO 2022-02-16